Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 substudy 03B in second-line metastatic renal cell carcinoma
2023-506839-15-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, belzutifan, mk-4830, favezelimab and 1 more in renal cell carcinoma (RCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more dose-limiting toxicities, Number of participants who experience one or more adverse events and 3 more. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-506839-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506839-15-00.